William Schuette -

 Living with Terminal Cancer 

''I am a 16 year lung cancer survivor with a 'story of hope' and the author of 'Living with Terminal Lung Cancer.' 

I hope you can spread the word about my book 'Living with Terminal Lung Cancer' by sending or sharing this book link with your family and friends. 

Royalties from the book sales will be donated to lung cancer research in America.

thanks in advance 

https://mybook.to/wtQa09 ''


World Cancer Day

On #WorldCancerDay 4th Febuary 2023, we are grateful for all the researchers, oncologists, nurses and pharmaceutical companies who are dedicated to #cancer #research and care. Your work matters deeply to us all.

Furthering Research into ALK+ Cancer Facebook Group

Do you or a member of your family have ALK-positive cancer and, if so, are you interested in hearing about or influencing the future of ALK+ cancer research? Why not join our Facebook group called “Furthering ALK+ cancer research by ALK+ International.”

We welcome anyone from the ALK community worldwide. We know we are alive today because of medical research. We are keen to come together to stay informed, share insights and advocate for more research. Together we can further ALK+ cancer research.


ICR Press release 

2023's Chair of Trustees Yvonne Diaz, recently appeared on BBC Radio 4 with representatives from Institute of Cancer Research to talk about the importance of biomarker testing. 

Talking with Cancer Podcast

Thanks to Katie Phillips for helping us to raise awareness during Lung Cancer Awareness Month of ALK+ lung cancer in her Talking with Cancer podcast. We appreciate Katie sharing her own connection with another genetic mutation - ROS1-which appear in lung cancer and other cancers just like ALK+.

ALK+ International launches, presents findings from patient perspective survey

On 8 Aug, ALK+ International became the first charity in the UK focused on funding research for ALK+ cancer. It also released its first European patient survey at the World Lung Cancer Conference (WLCC), 2022.

View the release here

View the survey results here

Support ALK+ International and join the conversation online.